Calprotectin – clinical and diagnostic value in rheumatoid arthritis
Open Access
- 1 September 2026
- journal article
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 13 (3) , 86-94
Abstract
Introduction. Rheumatoid arthritis is a systemic autoimmune disease in which persistent synovitis drives joint destruction and disability. Conventional biomarkers such as C-reactive protein and erythrocyte sedimentation rate are widely used to assess disease activity, but they fail to capture inflammation in a considerable proportion of patients and may be confounded by therapies such as interleukin-6 inhibition. Calprotectin (S100A8/A9, MRP8/14), a neutrophil- and monocytederived alarmin, has emerged as a potential biomarker reflecting the true inflammatory burden in rheumatoid arthritis. This review aimed to critically appraise the clinical and diagnostic value of calprotectin in adult rheumatoid arthritis, with emphasis on its relationship to disease activity, comparative performance against C-reactive protein and erythrocyte sedimentation rate, methodological aspects of measurement, and role in therapeutic monitoring. Material and methods. We systematically reviewed studies published between 2010 and 2025 that investigated calprotectin in adult rheumatoid arthritis, focusing on serum, plasma, synovial fluid, and fecal measurements, and their associations with disease activity, imaging, treatment response, and outcomes. Additionally, seminal articles published before 2010 were included when they provided essential historical context or foundational theoretical data relevant to the understanding of calprotectin in rheumatoid arthritis. Pediatric and animal studies were excluded. Results. Serum calprotectin is consistently elevated in rheumatoid arthritis compared with healthy controls and correlates strongly with swollen joint counts, composite indices, and ultrasound-detected synovitis, often outperforming C-reactive protein and erythrocyte sedimentation rate. Synovial fluid calprotectin is markedly increased, reflecting local production and aggressive synovitis, while fecal calprotectin has limited utility except in cases of concomitant gastrointestinal involvement. Importantly, calprotectin levels remain reliable in patients receiving IL-6 inhibitors, where C-reactive protein is suppressed. High baseline calprotectin predicts radiographic progression and poor functional outcomes, whereas declining levels parallel therapeutic response to DMARDs and biologics. Recent studies suggest calprotectin may help identify patients at risk of relapse during apparent remission, though its predictive value for treatment response to TNF inhibitors appears limited. Conclusions. Calprotectin is a sensitive biomarker of inflammation in rheumatoid arthritis, offering distinct advantages over traditional acute-phase reactants in detecting residual disease and guiding therapeutic monitoring. Standardisation of assays, establishment of validated cut-off values, and large prospective validation studies are required before routine integration into clinical practice.Keywords
This publication has 29 references indexed in Scilit:
- Annals of the Rheumatic Diseases2024
- Serum Calprotectin as an Inflammatory Marker in a Cohort of Egyptian Patients with Psoriatic Arthritis and its Correlation with Disease Activity and Radiological FindingsQJM: An International Journal of Medicine, 2024
- The potential role of serum amyloid A as biomarker of rheumatic diseases: a systematic review and meta-analysisClinical and Experimental Medicine, 2024
- Serum calprotectin correlates stronger with inflammation and disease activity in ACPA positive than ACPA negative rheumatoid arthritisRheumatology, 2023
- Temporal relationship between osteoarthritis and comorbidities: a combined case control and cohort study in the UK primary care settingRheumatology, 2021
- Calprotectin as a marker of inflammation in patients with early rheumatoid arthritisAnnals of the Rheumatic Diseases, 2017
- Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysisPostgraduate Medicine, 2017
- Serum Calprotectin Versus Acute‐Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor InhibitorsArthritis Care & Research, 2016
- Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactantsRheumatology, 2015
- Calprotectin in Rheumatoid ArthritisMolecular Diagnosis & Therapy, 2013